As in parental PC-3 tumors treated with VEGFR3-Ig (Fig 1), the density of lymphatic capillaries was decreased in VEGFR3-Ig-treated prostate tumors compared with lacZ-Ig-treated (Fig 7, 23 ± 4 μm/mm2vs. 123 ± 7 μm/mm2, p < 0.01). The gene discussed is FLT4; the disease is prostate neoplasm.